A Malignant Sertoli Cell Tumour of the Testis

Koppikar, Dhanwanti D.; Sirsat, M. V.

doi:10.1111/j.1464-410x.1973.tb12143.x

Cited by 26 publications

(4 citation statements)

References 7 publications

(4 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[25][26][27] Most are of the "not otherwise 4,19,20,[24][25][26][27][28] The features of SSCT were delineated in the seminal paper on the entity by Zukerberg et al 4 and characterized as Sertoli cells arranged in cords and tubules within a diffuse and prominent collagenous background. All but 1 case in that study were histologically benign, and follow-up in 5 patients (3 to 10 y; mean, 5.8 y), including the histologically malignant case, was unremarkable after orchiectomy alone.…”

Section: Discussionmentioning

confidence: 99%

Sclerosing Sertoli Cell Tumor of the Testis

Kao¹,

Kum²,

Idrees³

et al. 2014

American Journal of Surgical Pathology

View full text Add to dashboard Cite

Sclerosing Sertoli cell tumor (SSCT) of the testis is rare, with only 22 previously reported cases. Most have been small, circumscribed masses, and none has had a malignant clinical course; however, follow-up is limited. We have examined 20 new SSCTs to better characterize their features and report long-term follow-up. At least focal tubule formation by sex cord cells in a dense, hypocellular fibrous stroma occupying at least 50% of the lesion was required. The patient age ranged from 23 to 52 years (mean, 37; median, 39). All SSCTs were unilateral with 11 left sided and 9 right sided. The average size was 1.7 cm (range, 0.5 to 6 cm). In most cases, the stroma represented 50% to 70% of the mass but was at least 80% in 2. The Sertoli cells formed cords, trabeculae, small nests, focal tubules (sometimes with a vague pseudovascular or retiform appearance), and rarely single cells. Most tumor cells had small, round, oval to polygonal nuclei with finely granular chromatin, small nucleoli, and modest amounts of pale, eosinophilic cytoplasm. No mitotic figures, significant atypia, or necrosis was seen. All tumors but 1 were circumscribed and lacked lymphovascular invasion. Follow-up in 15 patients (3 mo to 16 y; mean, 6.1 y) showed 9 alive and free of disease, 5 alive with unknown disease status, and 1 patient, who presented with bone metastases, dead of disease at 27 months. The only features in the malignant case that differed from all others in our study were lymphovascular invasion and lack of circumscription. Combining our cases with previously reported ones shows that SSCTs are unilateral, usually small (80% <2 cm) tumors that occur in a wide age range (18 to 80 y old; mean, 35 y) and lack necrosis. Only 1 of 31 with follow-up (mean, 4.4 y) metastasized; this tumor was 3.8 cm and had lymphovascular invasion and invasive growth. We conclude that SSCTs<2 cm with the typical features and lacking those associated with malignancy in Sertoli cell tumors, not otherwise specified, have a negligible risk of metastasis and are adequately managed by orchiectomy alone.

show abstract

Section: Discussionmentioning

confidence: 99%

Sclerosing Sertoli Cell Tumor of the Testis

Kao¹,

Kum²,

Idrees³

et al. 2014

American Journal of Surgical Pathology

View full text Add to dashboard Cite

show abstract

“…The Sertoli cell tumours, named androbalstoma by Teilum, constitute 1-1.5% of the testicular tumours (3). The Sertoli cell tumours are generally benign tumours, but on reviewing the literature 19 cases were found with a malignant course and details of clinical data (4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20). A further 4 cases were reported to have had a malignant course, but clinical data are not available (21).…”

Section: Metastasizing Sertoli Cell Tumours Of and A Review Of The Literaturementioning

confidence: 99%

Metastasizing Sertoli Cell Tumours of the Human Testis—a Report of Two Cases and a Review of the Literature

Madsen

Hultberg

1990

Acta Oncologica

View full text Add to dashboard Cite

The median time to progression was 16 weeks for patients receiving doxorubicin and 5-FU and 24 weeks for patients receiving doxorubicin and ftorafur. This difference was not statistically significant. There was no significant difference in survival between groups I and 11. The median survival was 16 weeks for patients receiving doxorubicin and 5-FU and 25 weeks for patients receiving doxorubicin and ftorafur (Figure).Discussion. The non-haematological toxicity was very similar in the two treatment regimens. However, the incidence of diarrhea was significantly higher in the ftorafur/doxorubicin-treated group. Aside from diarrhea and nausea/vomiting there was no major non-haematological side-effects. We found increase of liver enzymes (SGOT) in 5 patients from each treatment a m ; this could not be attributed to drug toxicity, rather it indicated progressive disease. Kidney dysfunction has previously been reported (1) but was not observed in our series.Haematological toxicity was more severe in the 5-FU/doxorubicin-treated group, with 61% of the patients having a WBC nadir below 3 x 109/1 during the first cycle compared to only 28% in the ftorafur/doxorubicin-treated group. There was no significant depression of platelet count and all patients' platelet nadir during the first treatment course was above 150 x 109/l.Despite the difference in toxicity there was no difference in the number of treatment cycles in which it was necessary to reduce the dose (28% vs 23%). We therefore conclude that the overall toxicity is about the same for the two drugs when given in the doses used in this trial and in combination with doxorubicin.There was no difference in response to the two regimens, neither when assessed by time to progression nor as overall survival (Figure). The observed median survival in this trial was 16 weeks, which is in accordance with other reported results. In 33 trials including 1 100 patients the median survival was 22 weeks with a range of 7-38 weeks (10, 11).In conclusion, we found no survival or toxicity benefit of ftorafur over 5-FU in the treatment of gastric cancer.

show abstract

“…The risk of malignancy seems higher than previously considered, and so deceptive are the features and behaviour of this lesion (Koppikar and Sirsat, 1973) that we believe simple orchiectomy is no longer adequate treatment and that it should be complemented by retroperitoneal lymphadenectomy.…”

Section: Commentmentioning

confidence: 69%